PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-5 (5)
 

Clipboard (0)
None
Journals
Authors
more »
Year of Publication
1.  Cutaneous plasmacytoma 
doi:10.5045/kjh.2012.47.3.162
PMCID: PMC3464332  PMID: 23071470
2.  CXCR4 antagonists in hematologic malignancies: more than just mobilizers? 
The Korean Journal of Hematology  2011;46(4):209-210.
doi:10.5045/kjh.2011.46.4.209
PMCID: PMC3259509  PMID: 22259623
3.  Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro 
The Korean Journal of Hematology  2011;46(4):244-252.
Background
Antagonists of CXC chemokine receptor 4 (CXCR4), including AMD3100, induce peripheral mobilization of hematopoietic stem cells and have been approved for clinical use. We explored whether the CXCR4 antagonists affected the survival and proliferation of myeloid leukemia cells in vitro.
Methods
The effects of CXCR4 antagonists AMD3100 and T140 on the survival and proliferation of myeloid leukemia cell lines (U937, HL-60, MO7e, KG1a, and K562) as well as CD34+ cells obtained from patients with AML and CML were analyzed by flow cytometry by using annexin V and a colorimetric cell proliferation assay.
Results
AMD3100, but not T140, stimulated the proliferation of leukemia cells in vitro in a dose-dependent manner for up to 5 days (~2-fold increase at a concentration of 10-5 M), which was not abrogated by pretreatment of the cells with pertussis toxin, but was attenuated by RNAi knockdown of CXCR7 transcripts. In contrast, AMD3100 induced a marked decrease in the cell numbers after 5-7 days. AMD3100, but not T140, induced phosphorylation of MAPK p44/p42. AMD3100 increased the number and size of leukemia cell colonies and reduced cell apoptosis during the first 5-7 days of incubation, but the phenomena were reversed during the later period of incubation.
Conclusion
The effects of CXCR4 antagonists on the proliferation of myeloid leukemia cells are not uniform. AMD3100, but not T140, exerts dual effects, initially enhancing and subsequently inhibiting the survival and proliferation of the cells in vitro.
doi:10.5045/kjh.2011.46.4.244
PMCID: PMC3259516  PMID: 22259630
AMD3100; CXCR4; SDF-1; Myeloid leukemia; Cell proliferation; Apoptosis
4.  Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases 
The Korean Journal of Hematology  2011;46(2):111-117.
Background
There has been no report on the clinical features or natural history of autoimmune hemolytic anemia (AIHA) in the Korean adult population. This study retrospectively analyzed the clinical characteristics and long-term outcomes of AIHA in the Korean adults.
Methods
Patients newly diagnosed with AIHA between January 1994 and December 2010 at Chungnam National University Hospital were enrolled. Patient characteristics at diagnosis, response to treatment, and the natural course of the disease were documented.
Results
Thirty-two patients (31 females and 1 male) with a median age of 48 years (range, 17-86) were enrolled. Of these, 21.9% were initially diagnosed with secondary AIHA. Thirteen patients (40.6%) were initially diagnosed with Evans' syndrome. Of the 29 patients who were placed on therapy, 27 (93.1%) showed a partial response or better. Nevertheless, 1 year after initiating treatment, 80% of the patients were still treatment-dependent. During follow-up (median length 14 months; range, 0.5-238), 14 of 25 patients (56.0%) who were initially diagnosed with primary warm antibody AIHA were found to have systemic lupus erythematosus (SLE). Median time to conversion to SLE was 8.0 months (95% CI, 4.3-11.7), and the probabilities of conversion at 12 and 24 months were 63% and 91%, respectively. Younger age (<60 years) and a positive fluorescent anti-nuclear antibody test were associated with a higher probability of SLE conversion (P=0.01 and P<0.001, respectively).
Conclusion
Primary AIHA is rare. Regular, vigilant testing for SLE is required in patients initially diagnosed with AIHA.
doi:10.5045/kjh.2011.46.2.111
PMCID: PMC3128891  PMID: 21747883
Autoimmune hemolytic anemia; Evans' syndrome; Systemic lupus erythematosus; Thrombosis
5.  Long-term outcome of isolated thrombocytopenia accompanied by hypocellular marrow 
The Korean Journal of Hematology  2011;46(2):128-134.
Background
Hypocellularity of bone marrow (BM), not associated with significant dyshematopoiesis, is often found in patients with isolated thrombocytopenia, but its clinical implications have not been studied. We prospectively studied the clinical features and natural history of these patients.
Methods
Adults with isolated thrombocytopenia (platelet counts <100×109/L) in the absence of dyshematopoiesis, cytogenetic abnormalities, or megakaryocytic hyperplasia and who had BM hypocellularity (below 30% in patients aged less than 60 years; below 20% in patients aged 60 years or more) were enrolled at Chungnam National University Hospital between January 2002 and December 2006. They were monitored regularly for changes in platelet counts or development of additional cytopenia.
Results
Twenty patients (17 men and 3 women) were enrolled in the study. The median age was 29 years (range, 18-70 years). At initial presentation, the platelet counts ranged from 12×109/L to 99×109/L (median, 63×109/L) and were >50×109/L in 16 patients (80%). BM cellularity ranged from 5% to 25% (median, 15%) and was ≤10% in 6 patients (30%). During the median 48-month follow-up (range, 12-90 months), platelet counts of 3 of the 20 patients recovered to normal levels (>150×109/L) after 12, 56 and 66 months. Three patients developed pancytopenia after 11, 70 and 90 months. Two patients were consistent with moderate aplastic anemia, and 1 was confirmed as having refractory cytopenia with multilineage dysplasia. In the remainder of the patients, platelet counts remained unchanged.
Conclusion
Isolated thrombocytopenia accompanied by hypocellular marrow encompasses a group of heterogeneous conditions.
doi:10.5045/kjh.2011.46.2.128
PMCID: PMC3128894  PMID: 21747886
Thrombocytopenia; Idiopathic thrombocytopenic purpura; Bone marrow; Aplastic anemia; Myelodysplastic syndromes

Results 1-5 (5)